News
Public · Published
Alkermes Reports Q3 2026 Revenue of $480.1 Million and Adjusted EBITDA of $120.1 Million
Alkermes reported third-quarter 2026 revenue of $480.1 million, up from $394.2 million a year earlier, with GAAP net income of $16.3 million and adjusted EBITDA of $120.1 million. The company reiterated its 2026 financial expectations.
Published:
Updated:
What happened
Alkermes reported third-quarter 2026 revenue of $480.1 million, up from $394.2 million a year earlier, with GAAP net income of $16.3 million and adjusted EBITDA of $120.1 million. The company reiterated its 2026 financial expectations.
Confirmed
Global impact / market context
Revenue grew while operating income and net income fell sharply, showing costs rose faster than sales. This matters because profit per sale, that is margin, shrank, and the reiterated outlook signals management sees no need to change its plan despite weaker earnings.
Analyst inference
Adjusted EBITDA, which means earnings before interest, taxes, depreciation and amortization, was nearly flat year over year. Investors often treat this as a rough guide to cash generated from operations, so the steady figure suggests core cash generation held even as reported profit dropped.
Analyst inference
What to watch
- Watch whether operating income recovers from $36.0 million, given it was $89.1 million a year earlier, which shows cost pressure weighing on reported profit. Confirmed
- Watch whether the reiterated 2026 financial expectations are maintained in later updates, since the company gave no new figures against which progress can be measured. Proposed
- Watch the orexin clinical data readouts over the coming year, because results could shift spending plans and the cost base that drove this quarter's lower income. Analyst inference
Evidence
- Original source link unavailable